Welcome to our dedicated page for Greenwich Lifesciences news (Ticker: GLSI), a resource for investors and traders seeking the latest updates and insights on Greenwich Lifesciences stock.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) generates news primarily around the clinical and regulatory progress of GLSI-100, its investigational immunotherapy to prevent breast cancer recurrences, and the Phase III FLAMINGO-01 trial. Company press releases highlight milestones in patient screening and enrollment, preliminary clinical observations, regulatory designations, and trial expansion across the United States and Europe.
Readers following GLSI news can expect updates on FLAMINGO-01, including the number of patients screened, enrollment status in the HLA-A*02 and non-HLA-A*02 arms, and preliminary analyses of recurrence rates, immune responses, and safety. The company has reported that more than 1,000 patients have been screened and that the 250-patient non-HLA-A*02 open label arm is fully enrolled, with early analyses suggesting an approximately 80% reduction in recurrence rate after completion of the primary immunization series. These observations are described by the company as preliminary and subject to change as the trial matures.
News items also cover regulatory developments, such as the U.S. FDA granting Fast Track designation for GLSI-100 in the HLA-A*02 genotype population, and geographic expansion of FLAMINGO-01 into additional European countries, including Ireland, Portugal, Belgium, and Austria, following approvals from European regulators. Corporate strategy communications discuss clinical strategy, financing approaches such as at-the-market offerings, partnering activities, and oversight by the Data Safety Monitoring Board and Steering Committee.
For investors, clinicians, and observers, the GLSI news feed offers a consolidated view of how Greenwich LifeSciences describes the evolution of its lead program, including trial design refinements, interactions with regulators, and key governance decisions disclosed through SEC filings and press releases. Regularly reviewing these updates can help track the company’s reported progress in developing GLSI-100 for HER2-positive breast cancer patients.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) has announced its partnership as a Bronze sponsor for the Susan G. Komen Race for the Cure in Houston on October 2, 2021. The company will manage a water station and actively participate in the event. This collaboration underscores Greenwich's commitment to supporting breast cancer patients and survivors. The CEO emphasized the alignment of their goal to prevent metastatic breast cancer recurrence with the mission of the Komen foundation. The event aims to raise funds for breast cancer advocacy and research.
Greenwich LifeSciences (GLSI) announced that CEO Snehal Patel will present at the Benzinga Healthcare Small-Cap Conference on September 29-30, 2021. Patel's presentation is scheduled for September 29 at 9:30 am ET. The conference will connect investors with small-cap companies and features live presentations and educational sessions. Greenwich LifeSciences is focused on developing GP2, an immunotherapy designed to prevent breast cancer recurrences. Notably, in a Phase IIb trial, GP2 showed no recurrences after five years in treated patients.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) participates in the 2021 Cantor Virtual Global Healthcare Conference from September 27-30, 2021. CEO Snehal Patel will present virtually on September 29 at 2:00 PM ET and engage in one-on-one meetings with investors. The conference features over 300 companies and a keynote by Pfizer's CEO, Albert Bourla. Greenwich develops GP2, an immunotherapy aimed at preventing breast cancer recurrence in patients post-surgery, with promising Phase IIb trial results showing no recurrences after 5 years.
Greenwich LifeSciences, Inc. (GLSI) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. CEO Snehal Patel will present on demand starting September 13 and engage in one-on-one meetings with investors. The conference will feature key industry speakers and networking opportunities. Greenwich’s main focus is on its innovative GP2 immunotherapy aimed to prevent breast cancer recurrences, supported by successful Phase IIb clinical trial results.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI), a clinical-stage biopharmaceutical company, reports its significant achievements, including a 763% increase in share price since its IPO in February 2019, the highest among 307 biotech IPOs. The company is pleased with H.C. Wainwright's analyst coverage initiation on September 1, 2021, with a price target of $78 per share. It has also been added to the Russell 2000 index, enhancing its visibility to institutional investors. Upcoming updates on GP2 immunotherapy and Phase III clinical trial initiation are anticipated.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced its participation in Citi's 16th Annual BioPharma Virtual Conference, taking place from September 8-10, 2021. CEO Snehal Patel will engage in one-on-one meetings with investors. The conference features key discussions and presentations from leading pharma and biotech companies. Greenwich focuses on developing GP2, an immunotherapy aimed at preventing breast cancer recurrences. Previous Phase IIb trials showed no recurrences in high HER2 positive patients after treatment, and a Phase III trial is planned.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced its inclusion in the Russell 2000® and Russell 3000® Indexes effective June 28, 2021. This milestone is expected to boost institutional ownership and visibility for the company as it develops GP2, an immunotherapy aimed at preventing breast cancer recurrences. CEO Snehal Patel emphasized the significance of this addition and the plans for a Phase III clinical trial. The Russell Indexes are benchmarks for $10.6 trillion in assets, highlighting the potential for increased interest in GLSI.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) presented the final 5-year safety data of its GP2 immunotherapy at the 2021 ASCO Annual Meeting. The Phase IIb trial showed no serious adverse events related to GP2, with the majority experiencing mild injection site reactions. Notably, completion of the GP2 Primary Immunization Series led to a 0% recurrence rate in HER2 3+ patients over five years post-surgery. The findings support plans for a Phase III trial, leveraging the encouraging safety data to attract potential partners for co-development.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) has appointed Christine Fischette, Ph.D., as Vice President of Business Development. Dr. Fischette aims to expand the company’s pipeline and pursue strategic partnerships for its immunotherapy product, GP2, which has shown promising results in preventing breast cancer recurrences. The final safety data from a Phase IIb trial will be presented at the upcoming ASCO conference, which, if positive, could enhance GP2's market appeal. CEO Snehal Patel emphasized that Dr. Fischette's experience will be vital as they target new breast cancer markets.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) has announced the publication of a second poster detailing the GP2 Phase III clinical trial design at the 2021 AACR Annual Meeting. Led by Dr. Mothaffar F. Rimawi, the trial aims to treat up to 500 patients to evaluate GP2 as an immunotherapy to prevent breast cancer recurrences post-surgery. The trial is based on promising Phase IIb results showing 100% invasive Disease-Free Survival (iDFS) after 5 years. An interim analysis is planned, and the trial will explore expanding the treatment for various HLA types.